open access
Adjuvant treatments for non-small cell lung cancer
open access
Abstract
Surgery remains the cornerstone for the curative treatment of non-small cell lung cancer (NSCLC). Long-term survival depends on different prognostic factors including the tumour extent (the T and N stage) and the quality of the surgical resection (complete vs. incomplete resection, the type of mediastinal exploration). Nevertheless, only one-third of all operated patients will be metastases alive 5 years after the surgical resection. Failures are due to a loco-regional relapse, distant metastases or a second primary cancer related to the long story of tobacco abuse. The pattern of failure analysis should decide on the type of adjuvant treatment: a loco regional modality or a form of systemic treatment such as chemotherapy or immunotherapy.
Abstract
Surgery remains the cornerstone for the curative treatment of non-small cell lung cancer (NSCLC). Long-term survival depends on different prognostic factors including the tumour extent (the T and N stage) and the quality of the surgical resection (complete vs. incomplete resection, the type of mediastinal exploration). Nevertheless, only one-third of all operated patients will be metastases alive 5 years after the surgical resection. Failures are due to a loco-regional relapse, distant metastases or a second primary cancer related to the long story of tobacco abuse. The pattern of failure analysis should decide on the type of adjuvant treatment: a loco regional modality or a form of systemic treatment such as chemotherapy or immunotherapy.
About this articleTitle
Adjuvant treatments for non-small cell lung cancer
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
173-179
Published online
2001-01-01
DOI
10.1016/S1507-1367(01)70971-6
Bibliographic record
Rep Pract Oncol Radiother 2001;6(4):173-179.
Authors
Paul Van Houtte
F. Mornex
M. Roelandts